Table 2.
Number and percentage of participants within the study population and study collectives with prescriptions of medication with functional impact on the cytochromes, catalytic subunit, and transporters under study within the baseline year.
| Collective | Gene | Participants with inhibitor or antagonist prescription | Percentage within collective |
|---|---|---|---|
| Complete study population | CYP2C9 | 4058 | 37.76 |
| CYP2C19 | 3677 | 34.21 | |
| VKORC1 | 110 | 1.02 | |
| SLCO1B1 | 6327 | 58.87 | |
| ABCB1 | 7589 | 70.61 | |
| CYP3A4 | 5416 | 50.39 | |
| CYP3A5 | 35 | 0.33 | |
| Anticoagulant/antiplatelet | CYP2C9 | 3437 | 41.35 |
| CYP2C19 | 2913 | 35.04 | |
| VKORC1 | 0 | 0.00 | |
| SLCO1B1 | 5071 | 61.00 | |
| ABCB1 | 5999 | 72.16 | |
| CYP3A4 | 4232 | 50.91 | |
| CYP3A5 | 23 | 0.28 | |
| Cholesterol-lowering drug | CYP2C9 | 418 | 21.84 |
| CYP2C19 | 542 | 28.32 | |
| VKORC1 | 74 | 3.87 | |
| SLCO1B1 | 931 | 48.64 | |
| ABCB1 | 1222 | 63.85 | |
| CYP3A4 | 893 | 46.66 | |
| CYP3A5 | 9 | 0.47 | |
| Y57.9! | CYP2C9 | 203 | 38.96 |
| CYP2C19 | 222 | 42.61 | |
| VKORC1 | 36 | 6.91 | |
| SLCO1B1 | 325 | 62.38 | |
| ABCB1 | 368 | 70.63 | |
| CYP3A4 | 291 | 55.85 | |
| CYP3A5 | 3 | 0.58 |
Antagonists and inhibitors were identified according to respective entries on DrugBank Online, a database for drug and drug target information.